Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MrMugsyon Nov 28, 2020 11:05am
1049 Views
Post# 31994395

The news releases sure look like they could be plentiful ...

The news releases sure look like they could be plentiful ...No doubt we are now waiting for the reverse split.

Then comes the fun to get the share price up - and - if all goes well - to a US exchange as the share price approaches $10 (in my opinion ... $8-$10 will give us the green light / confidence to do so).  Smells like PRN's approach to the NASDAQ.

Take your pick for exciting updates to follow ... likely the comprehensive update first and it sure could be a doozy.  Likely to touch on everything that's underway right now ...

1. marketing work to select a proprietary brand name
2. collaboration on rare diseases
3. pipeline expansion initiative aimed at developing new IP based on H2S platform (assuming this is closely related to the academic study initiative)
4. progress on 352
5. small market partnering update
6. large market partnering update (now that the additional hires were added)
7. p3 program update and P3 enabling studies (8 of them underway)
8. updates to peak sales potential (already talking about $30B opportunity for OTENA in the latest TSX video)
9. update plan for additional indications for OTENA - maybe this gets updated after P3 begins
10. more detail on initiating a whole new field around gaseous mediators.

The nice thing is ... everything I mention in 1-10 above has informally been mentioned in ATE's presentation or in their news releases since our "Corporate Update" dated August 4, 2020.

So many things on the go - this seems primed for the big-times !!!

Good Luck Longs ... I think holding on to our shares was the best move going into 2021.  IMO.


<< Previous
Bullboard Posts
Next >>